Float Short %

15.8

Margin Of Safety %

Put/Call OI Ratio

0.07

EPS Next Q Diff

-0.07

EPS Last/This Y

0.44

EPS This/Next Y

-0.1

Price

1.14

Target Price

2.75

Analyst Recom

1.8

Performance Q

65.28

Relative Volume

0.5

Beta

1.21

Ticker: LXRX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	LXRX	1.24	0.08	0.01	53995
2025-08-18	LXRX	1.21	0.06	0.77	49385
2025-08-19	LXRX	1.16	0.06	1.53	49383
2025-08-20	LXRX	1.135	0.07	0.02	49794
2025-08-21	LXRX	1.17	0.07	0.00	50238
2025-08-22	LXRX	1.195	0.07	0.05	50375
2025-08-25	LXRX	1.13	0.07	0.11	50579
2025-08-26	LXRX	1.135	0.07	0.04	50618
2025-08-27	LXRX	1.135	0.07	0.01	50734
2025-08-28	LXRX	1.15	0.07	0.00	50915
2025-08-29	LXRX	1.11	0.07	0.33	51051
2025-09-02	LXRX	1.12	0.07	0.08	51365
2025-09-03	LXRX	1.09	0.07	0.45	51530
2025-09-04	LXRX	1.075	0.07	0.79	51612
2025-09-05	LXRX	1.09	0.07	0.01	51829
2025-09-08	LXRX	1.085	0.07	0.02	51978
2025-09-09	LXRX	1.125	0.07	0.13	52031
2025-09-10	LXRX	1.08	0.07	0.00	52311
2025-09-11	LXRX	1.11	0.07	0.01	52698
2025-09-12	LXRX	1.145	0.07	0.00	52911
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	LXRX	1.24	65.2	23.9	-0.19
2025-08-18	LXRX	1.21	65.2	30.8	-0.19
2025-08-19	LXRX	1.16	65.2	32.5	-0.19
2025-08-20	LXRX	1.13	65.2	30.6	-0.19
2025-08-21	LXRX	1.16	65.2	25.4	-0.19
2025-08-22	LXRX	1.20	65.2	26.3	-0.19
2025-08-25	LXRX	1.13	65.2	33.4	-0.19
2025-08-26	LXRX	1.14	65.2	27.6	-0.19
2025-08-27	LXRX	1.13	65.2	28.8	-0.19
2025-08-28	LXRX	1.15	65.2	26.6	-0.19
2025-08-29	LXRX	1.11	65.2	31.8	-0.19
2025-09-02	LXRX	1.12	65.2	27.1	-0.19
2025-09-03	LXRX	1.09	65.2	-2.1	-0.19
2025-09-04	LXRX	1.08	65.2	-5.2	-0.19
2025-09-05	LXRX	1.09	65.2	-8.3	-0.19
2025-09-08	LXRX	1.08	65.2	-4.6	-0.19
2025-09-09	LXRX	1.13	65.2	-12.4	-0.19
2025-09-10	LXRX	1.08	65.2	0.6	-0.19
2025-09-11	LXRX	1.11	65.2	-9.7	-0.19
2025-09-12	LXRX	1.14	65.2	-10.3	-0.19
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	LXRX	0.00	-8.03	15.28
2025-08-18	LXRX	0.00	-12.53	14.82
2025-08-19	LXRX	0.00	-12.53	14.82
2025-08-20	LXRX	0.00	-12.53	14.82
2025-08-21	LXRX	0.00	-12.53	14.82
2025-08-22	LXRX	0.00	-12.53	14.82
2025-08-25	LXRX	0.00	-9.78	14.82
2025-08-26	LXRX	0.00	-9.78	14.82
2025-08-27	LXRX	0.00	-9.78	15.28
2025-08-28	LXRX	0.00	-9.78	15.28
2025-08-29	LXRX	0.00	-9.78	15.28
2025-09-02	LXRX	0.00	-9.78	15.28
2025-09-03	LXRX	0.00	-9.78	15.28
2025-09-04	LXRX	0.00	-9.78	15.28
2025-09-05	LXRX	0.00	-9.78	15.28
2025-09-08	LXRX	0.00	-9.80	15.28
2025-09-09	LXRX	0.00	-9.80	15.28
2025-09-10	LXRX	0.00	-9.80	15.28
2025-09-11	LXRX	0.00	-9.80	15.80
2025-09-12	LXRX	0.00	-9.80	15.80
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.01

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

Institutional Transactions

-9.8

Beta

1.21

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

88.1

Max Drawdown 5-Year %

-96.8

Target Price

2.75

P/E

Forward P/E

PEG

P/S

7.15

P/B

3.23

P/Free Cash Flow

EPS

-0.33

Average EPS Est. Cur. Y

-0.19

EPS Next Y. (Est.)

-0.29

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-206.43

Relative Volume

0.5

Return on Equity vs Sector %

-118.1

Return on Equity vs Industry %

-104.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.2

EBIT Estimation

-10.3

Lexicon Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 103

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

stock quote shares LXRX – Lexicon Pharmaceuticals, Inc. Stock Price stock today

news today LXRX – Lexicon Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch LXRX – Lexicon Pharmaceuticals, Inc. yahoo finance google finance

stock history LXRX – Lexicon Pharmaceuticals, Inc. invest stock market

stock prices LXRX premarket after hours

ticker LXRX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: LXRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y